Drug Interactions with Plasticized PVCs
Source abstract
Abstract
Identifying the parameters that can impact the sorption of drugs to polymer materials is critical to design medical devices which would prevent drug loss by sorption. We propose a combined approach based on advanced molecular simulations and liquid chromatography experiments to investigate the adsorption of active pharmaceutical ingredients (API) onto plasticized PVC materials. The thermodynamic characterization of the adsorption was performed by the calculation of the Gibbs free energy profile, and the results were interpreted in light of experiments. We provide a microscopic description of the interfacial region formed by PVC chains, plasticizers, water, and drug molecules. The mobility of drugs on the PVC surfaces is correlated to the Gibbs free energy of adsorption. We demonstrate the complementarity of our approach which could guide future experiments and help the design of new medical devices.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Polymer Science and PVC · Effects and risks of endocrine disrupting chemicals · biodegradable polymer synthesis and properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CNRS, Clermont Auvergne INP, Institut de Chimie de Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Laboratoire des Multimatériaux et Interfaces, UMR CNRS 5615, Université de Lyon, Université Claude Bernard Lyon 1, 69622 Villeurbanne, France
CNRS, Clermont Auvergne INP, Institut de Chimie de Clermont-Ferrand, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Funding
Auvergne Rh?ones Alpes regional council
References (70)
Show source-provided references
1. Polyvinyl Chloride (PVC) Market - Growth, Trends, COVID - 19 Impact, and Forecasts (2021–2026). 2021; https://www.researchandmarkets.com/reports/4520150/polyvinyl-chloride-pvc-market-growth-trends (accessed 2022-02-12).
2. 10.3390/ma1404084410.3390/ma14040844 ↗
3. 10.1021/acs.macromol.8b0075610.1021/acs.macromol.8b00756 ↗
4. 10.1038/s41529-019-0080-710.1038/s41529-019-0080-7 ↗
5. European Union · 2008
6. ECHA, 2021. Information on chemicals; ECHA - Eur. Chem. Agency http://echa.europa.eu/information-on-chemicals (accessed 2022-02-12).
7. 2017
8. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) 2016. SCENIHR - opinions. Santé publique - European Commission. https://ec.europa.eu/health/scientific_committees/emerging/opinions_fr (accessed 2022-02-12).
9. 10.1016/S0378-5173(01)00735-910.1016/S0378-5173(01)00735-9 ↗
10. 10.1016/j.ijpharm.2008.10.02410.1016/j.ijpharm.2008.10.024 ↗
11. 10.1016/j.ijpharm.2016.04.04010.1016/j.ijpharm.2016.04.040 ↗
12. 10.1016/j.ijpharm.2015.08.03310.1016/j.ijpharm.2015.08.033 ↗
13. 10.1016/j.talanta.2016.10.03310.1016/j.talanta.2016.10.033 ↗
14. 10.1371/journal.pone.019236910.1371/journal.pone.0192369 ↗
15. 10.1038/s41598-019-55113-x10.1038/s41598-019-55113-x ↗
16. 10.1016/j.jpba.2004.10.02010.1016/j.jpba.2004.10.020 ↗
17. 10.1371/journal.pone.015491710.1371/journal.pone.0154917 ↗
18. 10.1371/journal.pone.020162310.1371/journal.pone.0201623 ↗
19. 10.1046/j.1440-1754.2000.00488.x10.1046/j.1440-1754.2000.00488.x ↗
20. 10.1177/19322968090030012610.1177/193229680900300126 ↗
21. 10.1016/j.cca.2014.02.03110.1016/j.cca.2014.02.031 ↗
22. Jin S.-E. · J. Vis. Exp. · 2017 · 121 · e55086
23. 10.1016/j.ijpharm.2017.05.04010.1016/j.ijpharm.2017.05.040 ↗
24. 10.1007/s40005-017-0364-210.1007/s40005-017-0364-2 ↗
25. 10.1016/j.jpba.2018.04.01110.1016/j.jpba.2018.04.011 ↗
26. 10.3390/pharmaceutics1310170910.3390/pharmaceutics13101709 ↗
27. 10.1080/0265203040002391110.1080/02652030400023911 ↗
28. 10.1080/0265203040002807610.1080/02652030400028076 ↗
29. 10.1016/j.ijpharm.2011.03.06010.1016/j.ijpharm.2011.03.060 ↗
30. 10.2166/wst.2016.21810.2166/wst.2016.218 ↗
31. 10.1021/acsami.1c0328410.1021/acsami.1c03284 ↗
32. 10.1016/j.ijpharm.2015.11.00410.1016/j.ijpharm.2015.11.004 ↗
33. Özeren H. D. · Mater. Design · 2020 · 187 · 10837
34. 10.1021/acsapm.0c0019110.1021/acsapm.0c00191 ↗
35. 10.1021/ct900214y10.1021/ct900214y ↗
36. 10.1063/1.473004010.1063/1.4730040 ↗
37. 10.1063/1.505405610.1063/1.5054056 ↗
38. 10.1016/j.fluid.2016.07.01810.1016/j.fluid.2016.07.018 ↗
39. 10.1002/jcc.2003510.1002/jcc.20035 ↗
40. 10.1103/PhysRevA.38.309810.1103/PhysRevA.38.3098 ↗
41. 10.1063/1.46491310.1063/1.464913 ↗
42. 10.1103/PhysRevLett.62.146910.1103/PhysRevLett.62.1469 ↗
43. 10.1021/ja00204a00110.1021/ja00204a001 ↗
44. 10.1021/ja00174a01110.1021/ja00174a011 ↗
45. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. Gaussian 16, Revision B.01; Gaussian, Inc.: Wallingford, CT, 2016.
46. 10.1063/1.212168710.1063/1.2121687 ↗
47. 10.1080/08927022.2013.84299410.1080/08927022.2013.842994 ↗
48. 10.1006/jcph.1995.103910.1006/jcph.1995.1039 ↗
49. 10.1016/0021-9991(77)90098-510.1016/0021-9991(77)90098-5 ↗
50. 10.1080/0026897830010285110.1080/00268978300102851 ↗
51. 10.1016/0010-4655(96)00043-410.1016/0010-4655(96)00043-4 ↗
52. 10.1016/0021-9991(77)90121-810.1016/0021-9991(77)90121-8 ↗
53. 10.1021/bi00151a03710.1021/bi00151a037 ↗
54. 10.1002/jcc.54013081210.1002/jcc.540130812 ↗
55. 10.1063/1.141097810.1063/1.1410978 ↗
56. Chipot C. · 200710.1007/978-3-540-38448-9 ↗
57. 10.1063/1.282986110.1063/1.2829861 ↗
58. 10.1021/jp506633n10.1021/jp506633n ↗
59. 10.1016/S0003-2670(00)01078-310.1016/S0003-2670(00)01078-3 ↗
60. 10.2174/092986701337264310.2174/0929867013372643 ↗
61. 10.1016/j.ijpharm.2004.08.00510.1016/j.ijpharm.2004.08.005 ↗
62. 10.1016/j.aca.2014.08.02510.1016/j.aca.2014.08.025 ↗
63. 10.1038/s41598-017-05964-z10.1038/s41598-017-05964-z ↗
64. Avdeef A. · 200310.1002/047145026X ↗
65. 10.1080/0026897060089306010.1080/00268970600893060 ↗
66. 10.1063/1.290445810.1063/1.2904458 ↗
67. 10.1002/jcc.2085210.1002/jcc.20852 ↗
68. 10.1021/jp107378s10.1021/jp107378s ↗
69. 10.1039/D0TA03419C10.1039/D0TA03419C ↗
70. 10.1063/1.46515810.1063/1.465158 ↗